275 related articles for article (PubMed ID: 14529727)
21. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Adler M; Keller JE; Sheridan RE; Deshpande SS
Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
[TBL] [Abstract][Full Text] [Related]
22. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A).
Restani L; Antonucci F; Gianfranceschi L; Rossi C; Rossetto O; Caleo M
J Neurosci; 2011 Nov; 31(44):15650-9. PubMed ID: 22049408
[TBL] [Abstract][Full Text] [Related]
23. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.
Wang L; Sun Y; Yang W; Lindo P; Singh BR
Toxicon; 2014 May; 82():52-60. PubMed ID: 24560879
[TBL] [Abstract][Full Text] [Related]
24. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
Wortzman MS; Pickett A
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
[TBL] [Abstract][Full Text] [Related]
25. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications.
de Almeida AT; De Boulle K
J Cosmet Laser Ther; 2007; 9 Suppl 1():17-22. PubMed ID: 17885882
[TBL] [Abstract][Full Text] [Related]
26. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.
Eleopra R; Tugnoli V; Rossetto O; De Grandis D; Montecucco C
Neurosci Lett; 1998 Nov; 256(3):135-8. PubMed ID: 9855358
[TBL] [Abstract][Full Text] [Related]
27. Studies on the dissociation of botulinum neurotoxin type A complexes.
Eisele KH; Fink K; Vey M; Taylor HV
Toxicon; 2011 Mar; 57(4):555-65. PubMed ID: 21195107
[TBL] [Abstract][Full Text] [Related]
28. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
Kutschenko A; Weisemann J; Kollewe K; Fiedler T; Alvermann S; Böselt S; Escher C; Garde N; Gingele S; Kaehler SB; Karatschai R; Krüger THC; Sikorra S; Tacik P; Wegner F; Wollmann J; Bigalke H; Wohlfarth K; Rummel A
Clin Neurophysiol; 2019 Jun; 130(6):1066-1073. PubMed ID: 30871800
[TBL] [Abstract][Full Text] [Related]
29. Characterization of Hemagglutinin Negative Botulinum Progenitor Toxins.
Kalb SR; Baudys J; Smith TJ; Smith LA; Barr JR
Toxins (Basel); 2017 Jun; 9(6):. PubMed ID: 28617306
[TBL] [Abstract][Full Text] [Related]
30. The Effect of Botulinum Neurotoxin Serotype a Heavy Chain on the Growth Related Proteins and Neurite Outgrowth after Spinal Cord Injury in Rats.
Wang YF; Liu F; Lan J; Bai J; Li XQ
Toxins (Basel); 2018 Feb; 10(2):. PubMed ID: 29393906
[TBL] [Abstract][Full Text] [Related]
31. Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: a 6-month prospective cohort study.
Alexander C; Elliott C; Valentine J; Stannage K; Bear N; Donnelly CJ; Shipman P; Reid S
Dev Med Child Neurol; 2018 Nov; 60(11):1165-1171. PubMed ID: 30151852
[TBL] [Abstract][Full Text] [Related]
32. Intramuscular pressure before and after botulinum toxin in chronic exertional compartment syndrome of the leg: a preliminary study.
Isner-Horobeti ME; Dufour SP; Blaes C; Lecocq J
Am J Sports Med; 2013 Nov; 41(11):2558-66. PubMed ID: 23969633
[TBL] [Abstract][Full Text] [Related]
33. Intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model.
Tinay I; Tanidir Y; Cikler E; Cetinel S; Tarcan T
Neurourol Urodyn; 2012 Apr; 31(4):564-70. PubMed ID: 22275224
[TBL] [Abstract][Full Text] [Related]
34. Repeated intrastriatal application of botulinum neurotoxin-A did not influence choline acetyltransferase-immunoreactive interneurons in hemiparkinsonian rat brain - A histological, stereological and correlational analysis.
Hawlitschka A; Berg C; Schmitt O; Holzmann C; Wree A; Antipova V
Brain Res; 2020 Sep; 1742():146877. PubMed ID: 32387181
[TBL] [Abstract][Full Text] [Related]
35. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
[TBL] [Abstract][Full Text] [Related]
36. Ouabain exacerbates botulinum neurotoxin-induced muscle paralysis via progression of muscle atrophy in mice.
Fujikawa R; Muroi Y; Unno T; Ishii T
J Toxicol Sci; 2010 Dec; 35(6):795-805. PubMed ID: 21139329
[TBL] [Abstract][Full Text] [Related]
37. Injection of high dose botulinum-toxin A leads to impaired skeletal muscle function and damage of the fibrilar and non-fibrilar structures.
Pingel J; Nielsen MS; Lauridsen T; Rix K; Bech M; Alkjaer T; Andersen IT; Nielsen JB; Feidenhansl R
Sci Rep; 2017 Nov; 7(1):14746. PubMed ID: 29116170
[TBL] [Abstract][Full Text] [Related]
38. Mechano- and metabosensitive alterations after injection of botulinum toxin into gastrocnemius muscle.
Caron G; Rouzi T; Grelot L; Magalon G; Marqueste T; Decherchi P
J Neurosci Res; 2014 Jul; 92(7):904-14. PubMed ID: 24615939
[TBL] [Abstract][Full Text] [Related]
39. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis.
Jurasinski CV; Lieth E; Dang Do AN; Schengrund CL
Toxicon; 2001 Sep; 39(9):1309-15. PubMed ID: 11384718
[TBL] [Abstract][Full Text] [Related]
40. Pre-Clinical Study of a Novel Recombinant Botulinum Neurotoxin Derivative Engineered for Improved Safety.
Vazquez-Cintron E; Tenezaca L; Angeles C; Syngkon A; Liublinska V; Ichtchenko K; Band P
Sci Rep; 2016 Aug; 6():30429. PubMed ID: 27484492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
